Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Significant Decrease in Short Interest

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 106,500 shares, a decrease of 43.4% from the January 31st total of 188,200 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily volume of 2,240,000 shares, the short-interest ratio is currently 0.0 days.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In other news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 23.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Cyclacel Pharmaceuticals in a research note on Thursday, February 27th. They issued a “sell” rating on the stock.

Cyclacel Pharmaceuticals Stock Down 0.4 %

CYCC stock opened at $0.32 on Tuesday. The company has a fifty day simple moving average of $0.36 and a two-hundred day simple moving average of $0.63. Cyclacel Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $4.00. The firm has a market capitalization of $2.02 million, a P/E ratio of -0.03 and a beta of 0.35.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.